Public-registry site landscape for NCT07723469, a TNBC - Triple-Negative Breast Cancer study sponsored by SURGE Therapeutics. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07723469 (registry record) |
| Sponsor | SURGE Therapeutics |
| Condition(s) | TNBC - Triple-Negative Breast Cancer |
| Phase | PHASE3 |
| Listed sites | 3 |
| Site countries | United States |
At NYU Langone Health — one of the facilities listed on this trial — 7 other studies are actively recruiting TNBC - Triple-Negative Breast Cancer patients at the same facility (public registry, as of July 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.
Eichor generates a preliminary site-risk snapshot for NCT07723469 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →